On 22 October 2007, orphan designation (EU/3/07/492) was granted by the European Commission to the Weinberg Group LLC, United Kingdom, for iodine (131I) chlorotoxin for the treatment of glioma.
The sponsorship was transferred to The Weinberg Group Limited, United Kingdom, in March 2009, to Biological Consulting Europe Ltd, United Kingdom, in December 2010 and subsequently to Eisai Europe Limited, in June 2011.
- What is glioma?
Tumours that begin in brain tissue are known as primary brain tumours. Primary brain tumours are named after the type of tissue from which they develop, the most common being gliomas, which begin in the glial (supportive) tissue. Patients affected by gliomas can suffer from severe symptoms of the nervous system, depending on where in the brain the tumour develops. Glioma is life-threatening.
- What is the estimated number of patients affected by the condition?
At the time of designation, glioma affected approximately 1 in 10,000 people in the European Union (EU)*. This is equivalent to a total of around 50,000 people, and is below the threshold for orphan designation, which is 5 people in 10,000. This is based on the information provided by the sponsor and knowledge of the Committee for Orphan Medicinal Products (COMP).
*Disclaimer: For the purpose of the designation, the number of patients affected by the condition is estimated and assessed on the basis of data from the European Union (EU 27), Norway, Iceland and Liechtenstein. This represents a population of 498,000,000 (Eurostat 2006).
- What treatments are available?
Treatment for glioma depends on a number of factors and includes different methods such as surgery, radiotherapy (using high-dose x-rays or other high-energy rays to kill cancer cells) or chemotherapy (using drugs to kill cancer cells), as well as some symptomatic treatments. Symptomatic treatments include certain steroid hormones (corticosteroids) to control the effects of raised pressure within the skull, and medication to help control seizures, as required. Several products for the treatment of glioma were authorised in the Community at the time of submission of the application for orphan designation.
Iodine (131I) chlorotoxin might be of potential significant benefit for the treatment of glioma because it might improve the long-term outcome of the patients. The assumption will have to be confirmed at the time of marketing authorisation. This will be necessary to maintain the orphan status.
- How is this medicine expected to work?
The product is a radioactive element (iodine 131) attached to a protein, which specifically binds to glioma cells. Iodine-131 can give off radiation, which in turn damages and kills cells, especially those that are dividing, such as cancer cells. Thus, it is expected that iodine (131I) chlorotoxin will build up in the glioma cancer cells, and then kill these cells with the radiation produced by the radioactive iodine contained in the molecule.
- What is the stage of development of this medicine?
The effects of Iodine (131I) chlorotoxin were evaluated in experimental models.
At the time of submission of the application for orphan designation, clinical trials in patients with glioma were ongoing.
Iodine (131I) chlorotoxin was not authorised anywhere in the world for glioma, at the time of submission. Orphan designation of Iodine (131I) chlorotoxin was granted in the United States for the treatment of malignant glioma.
According to Regulation (EC) No 141/2000 of 16 December 1999, the Committee for Orphan Medicinal Products (COMP) adopted on 12 September 2007 a positive opinion recommending the grant of the above-mentioned designation.
- Opinions on orphan medicinal product designations are based on the following three criteria:
- the seriousness of the condition;
- the existence of alternative methods of diagnosis, prevention or treatment;
- either the rarity of the condition (affecting not more than 5 in 10,000 people in the Community) or insufficient returns on investment.
Designated orphan medicinal products are products that are still under investigation and are considered for orphan designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of quality, safety and efficacy is necessary before a product can be granted a marketing authorisation.
|Name||Language||First published||Last updated|
|EU/3/07/492: Public summary of positive opinion of iodine (131I) chlorotoxin for the treatment of glioma||(English only)||2009-09-21||2011-09-06|
|Active substance||Iodine (131I) chlorotoxin|
|Disease/condition||Treatment of glioma|
|Date of decision||22/10/2007|
|Orphan decision number||EU/3/07/492|
Review of designation
Sponsor’s contact details:
Eisai Europe Limited
European Knowledge Centre
Herts AL10 9SN
Telephone: +44 (0) 845 676 5089
Telefax: +44 (0) 845 676 1504
For contact details of patients’ organisations whose activities are targeted at rare diseases see:
- Orphanet, a database containing information on rare diseases which includes a directory of patients’ organisations registered in Europe.
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.